Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye DiseaseBusiness Wire • 12/20/21
Do Options Traders Know Something About Aldeyra (ALDX) Stock We Don't?Zacks Investment Research • 12/15/21
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission GuidanceBusiness Wire • 11/09/21
Aldeyra's Dry Eye Disease Trial Meets Primary Endpoint, But Did Not Reach Statistical SignificanceBenzinga • 11/02/21
Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye DiseaseBusiness Wire • 11/02/21
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 10/28/21
Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate HighlightsBusiness Wire • 10/28/21
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business HighlightsBusiness Wire • 10/21/21
Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech SummitBusiness Wire • 09/09/21
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate HighlightsBusiness Wire • 08/05/21
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis PigmentosaBusiness Wire • 08/04/21
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business HighlightsBusiness Wire • 07/29/21
Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma CandidateBenzinga • 07/20/21
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal LymphomaBusiness Wire • 07/20/21
Aldeyra Therapeutics: A New Approach To Ocular Inflammatory Diseases With Impressive Clinical DataSeeking Alpha • 06/01/21
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare ConferenceBusiness Wire • 05/27/21
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business HighlightsBusiness Wire • 05/06/21